Charles C. Wu - Nov 20, 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role: Chief Executive Officer, Director
Signature: /s/ Ruoyu Chen, as attorney-in-fact for Charles C. Wu
Stock symbol: GYRE
Transactions as of: Nov 20, 2023
Transactions value $: $0
Form type: 4
Date filed: 11/22/2023, 07:20 PM
Previous filing: Nov 1, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GYRE	Stock Option (Right to Buy)	Award	$0	+170K		$0.00	170K	Nov 20, 2023	Common Stock	170K	$0.75	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
F2	These options are vested in full.

Content

Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.

These options are vested in full.